PET/CT helps predict survival of patients with prostate cancer

06/26/2013 | MolecularImaging.net

Metabolic imaging using 18F-FDG-PET/CT helps predict the overall survival of patients with castrate-resistant metastatic prostate cancer, according to a study published in The Journal of Nuclear Medicine. Data provided by the imaging method "may be useful in assessing the comparative effectiveness of various conventional and emerging treatment strategies," researchers said.

View Full Article in:

MolecularImaging.net

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ